clinical trial · NCT05025085
A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors
Advanced CancerAGEN1777a PD-1 inhibitor
brief summary
This study is a multicenter, Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of AGEN1777 as a single agent and when used in combination with a PD-1 inhibitor in participants with advanced, metastatic solid tumors.
started
Oct 4, 2021
primary completion
Jul 11, 2023
completion
Apr 1, 2024
last updated
Oct 15, 2025
official title
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol